References
Abdul-Ghani, M.A., Norton, L.,
DeFronzo, R.A. (2012). Efficacy and Safety of SGLT2 Inhibitors in the
Treatment of Type 2 Diabetes Mellitus. Current Diabetes Report ,
12: 230-238.
Alexander, S.P., Fabbro, D., Kelly,
E., Marrion, N.V., Peters, J.A., Faccenda, E., et al. (2017a).
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. British
Journal Pharmacology , 174(Suppl 1): S272-S359.
Alexander, S.P., Peters, J.A., Kelly,
E., Marrion, N.V., Faccenda, E., Harding, S.D., et al. (2017b).
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand-gated ion channels.British Journal Pharmacology , 174(Suppl 1): S130-S159.
Birkeland, K.I., Jørgensen, M.E.,
Carstensen, B., Persson, F., Gulseth, H.L., Thuresson, M., et al.(2017). Cardiovascular mortality and morbidity in patients with type 2
diabetes following initiation of sodium-glucose co-transporter-2
inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a
multinational observational analysis. The Lancet Diabetes &
Endocrinology, 5: 709-717.
Chao, E.C., Henry R.R. (2010). SGLT2
inhibition — a novel strategy for diabetes treatment. Nature
Reviews Drug Discovery, 9: 551-559.
Cheng, X.D., Wei, M.G. (2014).
Profiling the metabolism of astragaloside IV by ultra performance liquid
chromatography coupled with quadrupole/time-of-flight mass spectrometry.Molecules , 19: 18881-18896.
Chonlaket, P., Wongwan, T., Soodvilai,
S. (2018). Liver X receptor activation inhibits SGLT2-mediated glucose
transport in human renal proximal tubular cells. Experimental
physiology , 103: 250-260.
Dow, C., Mancini, F., Rajaobelina, K.,
Boutron-Ruault, M.C., Balkau, B., Bonnet, F., et al. (2018). Diet
and risk of diabetic retinopathy: a systematic review. European
journal of epidemiology, 33: 141-156.
Filippas-Ntekouan, S., Filippatos,
T.D., Elisaf, M.S. (2018). SGLT2 inhibitors: are they safe?Postgrad Med , 130: 72-82.
Gerstein, H.C., Miller, M.E.,
Byington, R.P., Goff, D.C., Bigger, J.T., Buse, J.B., et al.(2008). Effects of intensive glucose lowering in type 2 diabetes.The New England journal of medicine, 358: 2545-2559.
Guido, M.C., Marques, A.F., Tavares,
E.R., Tavares de Melo, M.D., Salemi, V.M.C., Maranhao, R.C. (2017). The
Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative
Stress, Inflammatory Cells, and Fibrosis between Subendocardial and
Interstitial Myocardial Areas. Oxidative medicine and cellular
longevity , 2017: 5343972.
Han, E., Jang, S.Y., Kim, G, Lee,
Y.H., Choe, E.Y., Nam, C.M., et al. (2016). Rosiglitazone Use and
the Risk of Bladder Cancer in Patients With Type 2 Diabetes.Medicine , 95: e2786.
Harding, S.D., Sharman, J.L.,
Faccenda, E., Southan, C., Pawson, A.J., Ireland, S., et al.(2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and
expansion to encompass the new guide to IMMUNOPHARMACOLOGY.Nucleic acids research, 46: D1091-D1106.
Hostalek, U., Gwilt, M., &
Hildemann, S. (2015). Therapeutic Use of Metformin in Prediabetes and
Diabetes Prevention. Drugs , 75: 1071-1094.
Ikonomidis, I., Pavlidis, G.,
Lambadiari, V., Kousathana, F., Triantafyllidi, H., Varoudi, M.,
et al. (2016). Improvement of arterial stiffness and LV myocardial
deformation in patients with coronary artery disease and diabetes
mellitus type 2 after 6-month treatment with metformin and agonists of
GLP-1R. European Heart Journal , 37: 176-177.
Lam, K.S., Chow, C.C., Tan, K.C., Ma,
R.C., Kong, A.P., Tong, P.C., et al. (2016). Practical
considerations for the use of sodium-glucose co-transporter type 2
inhibitors in treating hyperglycemia in type 2 diabetes. Current
Medical Research Opinion , 32: 1097-1108.
Liu, X., Wang, W., Song, G., Wei, X.,
Zeng, Y., Han, P., et al. (2017). Astragaloside IV ameliorates
diabetic nephropathy by modulating the mitochondrial quality control
network. PloS one , 12: e0182558.
Liu, Y., Liu, W., Li, J., Tang, S.,
Wang, M., Huang, W., et al. (2019). A polysaccharide extracted
from Astragalus membranaceus residue improves cognitive dysfunction by
altering gut microbiota in diabetic mice. Carbohydrate Polymers ,
205: 500-512.
Lu, W.S., Li, S., Guo, W.W., Chen,
L.L., Li, Y.S. (2015). Effects of Astragaloside IV on diabetic
nephropathy in rats. Genetics and molecular research. Genetics
Molecular Research , 14: 5427-5434.
Lu, Y.T., Ma, X.L., Xu, Y.H., Hu, J.,
Wang, F., Qin, W.Y., et al. (2018). A Fluorescent Glucose
Transport Assay for Screening SGLT2 Inhibitors in Endogenous
SGLT2-Expressing HK-2 Cells. Natural Product Bioprospect ,
9: 13-21.
Monami, M., Dicembrini, I., Mannucci,
E. (2017). Effects of SGLT-2 inhibitors on mortality and cardiovascular
events: a comprehensive meta-analysis of randomized controlled trials.Acta diabetologica , 54: 19-36.
Moucheraud, C., Lenz, C., Latkovic,
M., Wirtz, V.J. (2019). The costs of diabetes treatment in low- and
middle-income countries: a systematic review. BMJ global health ,
4: e001258.
Naito, R., Miyauchi, K. (2017).
Coronary Artery Disease and Type 2 Diabetes Mellitus Current Treatment
Strategies and Future Perspective. International Heart Journal ,
58: 475-480.
Nauck, M.A. (2014). Update on
developments with SGLT2 inhibitors in the management of type 2 diabetes.Drug design, development and therapy, 8: 1335-1380.
Navarro-Perez, J., Orozco-Beltran,
D., Gil-Guillen, V., Pallares, V., Valls, F., Fernandez, A. et
al. (2018). Mortality and cardiovascular disease burden of uncontrolled
diabetes in a registry-based cohort: the ESCARVAL-risk study. BMC
cardiovascular disorders , 18: 180.
Pandey, A., Chawla, S., Guchhait, P.
(2015). Type-2 diabetes: Current understanding and future perspectives.IUBMB life, 67: 506-513.
Pernicova, I., Korbonits, M. (2014).
Metformin—mode of action and clinical implications for diabetes and
cancer. Nature Reviews Endocrinology, 10: 143.
Pop-Busui, R., Braffett, B.H.,
Zinman, B., Martin, C., White, N.H., Herman, W.H., et al. (2017).
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the
Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study. Diabetes Care ,
40: 94-100.
Ran, R.X., Zhang, C.Z., Li, R.S.,
Chen, B.W., Zhang, W.H., Zhao, Z.Y., et al. (2016). Evaluation
and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone
Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms.Molecules, 21.
Reid, J., Rana, K., Niman, S.,
Sheikh-Ali, M., Lewis, T., Choksi, R.R., et al. (2020).
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular
Disease Prevention. American Journal of Cardiovascular Drug ,
1-11.
Ren, C., Liu, W., Li, J., Cao, Y.,
Xu, J., Lu, P. (2019). Physical activity and risk of diabetic
retinopathy: a systematic review and meta-analysis. Acta
diabetologica , 56(1): 823-837.
Rieg, T., Vallon, V. (2018).
Development of SGLT1 and SGLT2 inhibitors. Diabetologia ,
61: 2079-2086.
Rives, M.L., Javitch, J.A.,
Wickenden, A.D. (2017). Potentiating SLC transporter activity: Emerging
drug discovery opportunities. Biochemcal Pharmacology ,
135: 1-11.
Rodbard, H.W., Blonde, L.,
Braithwaite, S.S., Brett, E.M., Cobin, R.H., Handelsman, Y., et
al. (2007). American Association of Clinical Endocrinologists medical
guidelines for clinical practice for the management of diabetes
mellitus. Endocrinology Practice , 13(Suppl 1): 1-68.
Scheen, A.J. (2017). Dapagliflozin
and saxagliptin tablets for adults with type 2 diabetes. Expert
review of clinical pharmacology, 10: 1303-1316.
Shan, G., Zhou, X.J., Xia, Y., Qian,
H.J. (2016). Astragalus membranaceus ameliorates renal interstitial
fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo
and in vitro. Experimental Therapeutic Medicine , 11:1611-1616.
Shyangdan, D.S., Uthman, O.A., Waugh,
N. (2016). SGLT-2 receptor inhibitors for treating patients with type 2
diabetes mellitus: a systematic review and network meta-analysis.BMJ open , 6: e009417.
Szabo, N.J. (2014). Dietary safety of
cycloastragenol from Astragalus spp.: Subchronic toxicity and
genotoxicity studies. Food Chemical Toxicology , 64:322-334.
Tang, F., Hao, Y., Zhang, X., Qin, J.
(2017). Effect of echinacoside on kidney fibrosis by inhibition of
TGF-beta1/Smads signaling pathway in the db/db mice model of diabetic
nephropathy. Drug design, development and therapy, 11:2813-2826.
Tao, S., Li, L., Li, L., Liu, Y.,
Ren, Q., Shi, M., et al. (2019). Understanding the gut-kidney
axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus
and healthy controls: an analysis of the gut microbiota composition.Acta diabetologica , 56: 581-592.
Vaduganathan, M., Butler, J. (2019).
SGLT-2 inhibitors in heart failure: a new therapeutic avenue.Nature Medicine , 25: 1653-1654.
Vaidya, V., Gangan, N., Sheehan, J.
(2015). Impact of cardiovascular complications among patients with Type
2 diabetes mellitus: a systematic review. Expert Review
Pharmacoeconomics Outcomes, 15: 487-497.
Vivian, E.M. (2015). Dapagliflozin: a
new sodium-glucose cotransporter 2 inhibitor for treatment of type 2
diabetes. American journal of health-system pharmacy ,
72: 361-372.
Wang, X.X., Levi, J., Luo, Y.,
Myakala, K., Herman-Edelstein, M., Qiu, L., et al. (2017). SGLT2
Protein Expression Is Increased in Human Diabetic Nephropathy. The
Journal of biological chemistry , 292: 5335-5348.
Wang, Z.S., Xiong, F., Xie, X.H.,
Chen, D., Pan, J.H., Cheng, L. (2015). Astragaloside IV attenuates
proteinuria in streptozotocin-induced diabetic nephropathy via the
inhibition of endoplasmic reticulum stress. BMC Nephrology ,16:
44.
Wood, I,S,, Trayhurn, P, (2003).
Glucose transporters (GLUT and SGLT): expanded families of sugar
transport proteins. British Journal Nutrition , 89: 3-9.
Wright, E.M., Loo, D.D.F., Hirayama,
B.A. (2011). Biology of Human Sodium Glucose Transporters.Physiological Review , 91: 733-794.
Xu, M.E., Xiao, S.Z., Sun, Y.H.,
Ou-Yang, Y., Zheng, X.X. (2006). Effects of astragaloside IV on
pathogenesis of metabolic syndrome in vitro. Acta Pharmacol Sin,27: 229-236.
Yu, J., Zhang, Y., Sun, S., Shen, J.,
Qiu, J., Yin, X., et al. (2006). Inhibitory effects of
astragaloside IV on diabetic peripheral neuropathy in rats.Canadian journal of physiology and pharmacology, 84:579-587.
Yue, S.J., Liu, J., Feng, W.W.,
Zhang, F.L., Chen, J.X., Xin, L.T., et al. (2017). System
Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi
and Huanglian for Diabetes Mellitus. Front Pharmacology, 8. 694.
Zhang, J., Wu, C., Gao, L., Du, G.,
Qin, X. (2020). Astragaloside IV derived from Astragalus membranaceus: A
research review on the pharmacological effects. Advanced
Pharmacology , 87: 89-112.
Zhang, N., Wang, X.H., Mao, S.L.,
Zhao, F. (2011). Astragaloside IV improves metabolic syndrome and
endothelium dysfunction in fructose-fed rats. Molecules ,
16: 3896-3907.
Zhou, R.N, Song, Y.L., Ruan, J.Q.,
Wang, YT, Yan, R. (2012). Pharmacokinetic Evidence on the Contribution
of Intestinal Bacterial Conversion to Beneficial Effects of
Astragaloside IV, a Marker Compound of Astragali Radix, in Traditional
Oral Use of the Herb. Drug Metabolism Pharmacokonet , 27:586-597.
Zhou, X., Sun, X., Gong, X., Yang,
Y., Chen, C., Shan, G., et al. (2017). Astragaloside IV from
Astragalus membranaceus ameliorates renal interstitial fibrosis by
inhibiting inflammation via TLR4/NF-small ka, CyrillicB in vivo and in
vitro. International Immunopharmacolology, 42: 18-24.